MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research to evaluate a number of intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Main trial objectives were To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis patients, whilst one of the https://nickm777alw0.daneblogger.com/profile